References
- Lenschow, D. J., T. L. Walunas, and J. A. Bluestone. 1996. CD28/B7 system of T cell costimulation. Annu. Rev. Immunol. 14: 233-258. https://doi.org/10.1146/annurev.immunol.14.1.233
- Lafferty, K. J., S. J. Prowse, C. J. Simeonovic, and H. S. Warren. 1983. Immunobiology of tissue transplantation: a return to the passenger leukocyte concept. Annu. Rev. Immunol. 1: 143-173. https://doi.org/10.1146/annurev.iy.01.040183.001043
- June, C. H., J. A. Bluestone, L. M. Nadler, and C. B. Thompson. 1994. The B7 and CD28 receptor families. Immunol. Today 15: 321-331. https://doi.org/10.1016/0167-5699(94)90080-9
- Salomon, B. and J. A. Bluestone. 2001. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu. Rev. Immunol. 19: 225-252. https://doi.org/10.1146/annurev.immunol.19.1.225
- Greenfield, E. A., K. A. Nguyen, and V. K. Kuchroo. 1998. CD28/B7 costimulation: a review. Crit. Rev. Immunol. 18: 389-418. https://doi.org/10.1615/CritRevImmunol.v18.i5.10
- Walunas, T. L., D. J. Lenschow, C. Y. Bakker, P. S. Linsley, G. J. Freeman, J. M. Green, C. B. Thompson, and J. A. Bluestone. 1994. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1: 405-413. https://doi.org/10.1016/1074-7613(94)90071-X
- Teft, W. A., M. G. Kirchhof, and J. Madrenas. 2006. A molecular perspective of CTLA-4 function. Annu. Rev. Immunol. 24: 65-97. https://doi.org/10.1146/annurev.immunol.24.021605.090535
- Lenschow, D. J., Y. Zeng, J. R. Thistlethwaite, A. Montag, W. Brady, M. G. Gibson, P. S. Linsley, and J. A. Bluestone. 1992. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg. Science 257: 789-792. https://doi.org/10.1126/science.1323143
- Turka, L. A., P. S. Linsley, H. Lin, W. Brady, J. M. Leiden, R. Q. Wei, M. L. Gibson, X. G. Zheng, S. Myrdal, and D. Gordon, et al. 1992. T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc. Natl. Acad. Sci. U. S. A. 89: 11102-11105. https://doi.org/10.1073/pnas.89.22.11102
- Li, W., L. Lu, Z. Wang, L. Wang, J. J. Fung, A. W. Thomson, and S. Qian. 2001. Costimulation blockade promotes the apoptotic death of graft-infiltrating T cells and prolongs survival of hepatic allografts from FLT3L-treated donors. Transplantation 72: 1423-1432. https://doi.org/10.1097/00007890-200110270-00016
- Larsen, C. P., T. C. Pearson, A. B. Adams, P. Tso, N. Shirasugi, E. Strobert, D. Anderson, S. Cowan, K. Price, J. Naemura, J. Emswiler, J. Greene, L. A. Turk, J. Bajorath, R. Townsend, D. Hagerty, P. S. Linsley, and R. J. Peach. 2005. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am. J. Transplant. 5: 443-453. https://doi.org/10.1111/j.1600-6143.2005.00749.x
- Park, C. G., N. W. Thiex, K. M. Lee, G. L. Szot, J. A. Bluestone, and K. D. Lee. 2003. Targeting and blocking B7 costimulatory molecules on antigen-presenting cells using CTLA4Ig-conjugated liposomes: in vitro characterization and in vivo factors affecting biodistribution. Pharm. Res. 20: 1239- 1248. https://doi.org/10.1023/A:1025057216492
- Lacy, P. E. and M. Kostianovsky. 1967. Method for the isolation of intact islets of Langerhans from the rat pancreas. Diabetes 16: 35-39.
- Abrams, J. R., M. G. Lebwohl, C. A. Guzzo, B. V. Jegasothy, M. T. Goldfarb, B. S. Goffe, A. Menter, N. J. Lowe, G. Krueger, M. J. Brown, R. S. Weiner, M. J. Birkhofer, G. L. Warner, K. K. Berry, P. S. Linsley, J. G. Krueger, H. D. Ochs, S. L. Kelley, and S. Kang. 1999. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J. Clin. Invest. 103: 1243-1252. https://doi.org/10.1172/JCI5857
- Genovese, M. C., J. C. Becker, M. Schiff, M. Luggen, Y. Sherrer, J. Kremer, C. Birbara, J. Box, K. Natarajan, I. Nuamah, T. Li, R. Aranda, D. T. Hagerty, and M. Dougados. 2005. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N. Engl. J. Med. 353: 1114- 1123. https://doi.org/10.1056/NEJMoa050524
- Kremer, J. M., R. Westhovens, M. Leon, E. Di Giorgio, R. Alten, S. Steinfeld, A. Russell, M. Dougados, P. Emery, I. F. Nuamah, G. R. Williams, J. C. Becker, D. T. Hagerty, and L. W. Moreland. 2003. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N. Engl. J. Med. 349: 1907-1915. https://doi.org/10.1056/NEJMoa035075
- Kaplan, B. 2010. Belatacept: the promises and challenges of belatacept and costimulatory blockade. Am. J. Transplant. 10: 441-442. https://doi.org/10.1111/j.1600-6143.2010.03026.x
- Larsen, C. P., J. Grinyó, J. Medina-Pestana, Y. Vanrenterghem, F. Vincenti, B. Breshahan, J. M. Campistol, S. Florman, C. Rial Mdel, N. Kamar, A. Block, G. Di Russo, C. S. Lin, P. Garg, and B. Charpentier. 2010. Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies. Transplantation 90: 1528-1535. https://doi.org/10.1097/TP.0b013e3181ff87cd
- Vincenti, F., G. Blancho, A. Durrbach, P. Friend, J. Grinyo, P. F. Halloran, J. Klempnauer, P. Lang, C. P. Larsen, F. Mühlbacher, B. Nashan, J. P. Soulillou, Y. Vanrenterghem, T. Wekerle, M. Agarwal, S. Gujrathi, J. Shen, R. Shi, R. Townsend, and B. Charpentier. 2010. Five-year safety and efficacy of belatacept in renal transplantation. J. Am. Soc. Nephrol. 21: 1587-1596. https://doi.org/10.1681/ASN.2009111109
- Vincenti, F., B. Charpentier, Y. Vanrenterghem, L. Rostaing, B. Bresnahan, P. Darji, P. Massari, G. A. Mondragon-Ramirez, M. Agarwal, G. Di Russo, C. S. Lin, P. Garg, and C. P. Larsen. 2010. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am. J. Transplant. 10: 535-546. https://doi.org/10.1111/j.1600-6143.2009.03005.x
- Durrbach, A., J. M. Pestana, T. Pearson, F. Vincenti, V. D. Garcia, J. Campistol, C. Rial Mdel, S. Florman, A. Block, G. Di Russo, J. Xing, P. Garg, and J. Grinyó. 2010. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am. J. Transplant. 10: 547-557. https://doi.org/10.1111/j.1600-6143.2010.03016.x
- Alegre, M. L., J. Y. Tso, H. A. Sattar, J. Smith, F. Desalle, M. Cole, and J. A. Bluestone. 1995. An anti-murine CD3 monoclonal antibody with a low affinity for Fc gamma receptors suppresses transplantation responses while minimizing acute toxicity and immunogenicity. J. Immunol. 155: 1544-1555.
Cited by
- Considerations of critical quality attributes in the analytical comparability assessment of biosimilar products vol.48, pp.None, 2013, https://doi.org/10.1016/j.biologicals.2017.04.005